Phase 1 Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 20 years or older who are able to understand and agree to the study requirements, including blood tests and scans
• People who have been diagnosed with prostate cancer (a specific type called adenocarcinoma) that has spread to other parts of the body and is no longer responding to hormone-lowering treatments (known as metastatic castration-resistant prostate cancer)
• People who have had their testicles surgically removed, or who are receiving ongoing hormone-suppressing injections or implants, with testosterone levels confirmed to be very low (below 50 ng/dL)
• People who have previously received at least one course of taxane-based chemotherapy and at least one hormone-blocking medication (such as abiraterone, enzalutamide, apalutamide, or darolutamide), unless a doctor determined these were not medically suitable
• People who have previously received a type of targeted radiation treatment called lutetium-177 PSMA therapy, unless a doctor determined it was not suitable or the person declined it
• People whose cancer is confirmed to be getting worse, shown by rising PSA blood test results on at least two separate occasions at least one week apart, or by new or growing areas of cancer seen on scans
• People whose cancer shows strong uptake on a specialised PSMA PET/CT scan (a type of imaging that detects a protein on prostate cancer cells) performed within the past 12 weeks
• People with a life expectancy of at least 6 months and who are reasonably able to carry out daily activities (as assessed by a standard medical scale)
• People with blood counts and organ function results within acceptable ranges, including healthy enough levels of red blood cells, white blood cells, platelets, kidney function, and liver function
• People who are willing to use appropriate barrier contraception during the study if sexually active

Who may not be able to join:

• People who have had a previous allergic reaction to PSMA-targeted treatments or to radioactive metal compounds used in similar therapies
• People who have received radioligand therapy (either radium-223 or lutetium-177 PSMA) within the past 6 months
• People who have had surgery or radiation treatment within the past 4 weeks
• People who have received any systemic prostate cancer treatment within the past 4 weeks, including hormone-blocking drugs, chemotherapy, or PARP inhibitor medications
• People whose cancer scans show a pattern where the cancer is active on one type of scan (FDG PET) but shows very little uptake on the PSMA scan, suggesting the cancer may not respond well to PSMA-targeted treatment (confirm with trial site)
• People with a blockage in the urinary tract causing kidney swelling (hydronephrosis) that has not already been treated
• People with brain metastases or cancer affecting the lining around the brain or spinal cord that are causing symptoms, or with spinal cord compression, unless these have already been appropriately treated
• People who have another active cancer that currently requires systemic treatment
• People with serious heart conditions, such as a recent heart attack or unstable chest pain
• People with another severe or uncontrolled illness, including uncontrolled infections, that could put them at risk during the study

Important: Always verify eligibility with the trial site directly before applying.